Takeda began workforce reductions in the U.S. tied to a multiyear restructuring plan aimed at more than ¥200 billion ($1.26 billion) in annual cost savings. A WARN notice filed in Massachusetts indicates 634 positions affected, including 247 roles in Cambridge and 387 roles across other states. Takeda said notifications would start immediately, but the changes won’t take effect until July 2026, after new CEO Julie Kim formally takes the helm. The company also stated headcount reductions could evolve as employees seek and accept redeployment opportunities. The move continues a broader efficiency push that intensified after Vyvanse exclusivity losses and other portfolio shifts, including earlier actions affecting cell therapy roles and neuroscience field-based positions—underscoring continued cost pressure across large biopharma.